THE ARTICULAR CARTILAGE REPAIR DILEMMA Symptomatic Articular Cartilage Degeneration

The symptomatic degeneration of articular cartilage and associated arthritis is among the most prevalent chronic conditions in the United States and the population most at risk is increasing. It is the leading cause of limitations in activities of daily living and is second to heart disease in causing work disability. The current and future socioeconomic impact of chronic articular cartilage disease on the healthcare system will be magnified by increasing numbers of patients who will seek relief of their symptoms and their disability to remain active. Because these individuals live longer and remain active, the proportion of their life living with symptoms and disability from articular cartilage degeneration increases. The economic, psychologic, and social impact of degenerative articular cartilage can be enormous for these individuals but it also impacts their family and society. The direct traditional medical costs and indirect economic and wage loss from arthritis in individuals the United States has reached in excess of $65 billion annually and is expected to increase as the population ages. In addition, the expenditures for complementary and alternative professional services and therapies for arthritis is increasing and is also in the billions of dollars annually. Because of these escalating costs, documenting the value of the patient and cost effectiveness to society of prevention and treatment programs for symptomatic articular cartilage degeneration will be required.

[1]  Hirsch Hs Total joint replacement: a cost-effective procedure for the 1990s. , 1998 .

[2]  R. Kessler,et al.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.

[3]  V. Benson,et al.  Current estimates from the National Health Interview Survey, 1995. , 1998, Vital and health statistics. Series 10, Data from the National Health Survey.

[4]  S. Furner,et al.  Musculoskeletal Conditions in the United States , 1992 .

[5]  D. Bates,et al.  Costs, Outcomes, and Patient Satisfaction by Provider Type for Patients with Rheumatic and Musculoskeletal Conditions: A Critical Review of the Literature and Proposed Methodologic Standards , 1997, Annals of Internal Medicine.

[6]  D. Kingsley,et al.  Role of the mouse ank gene in control of tissue calcification and arthritis. , 2000, Science.

[7]  R. Chang,et al.  A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. , 1997, JAMA.

[8]  C. Schoenborn,et al.  Current estimates from the National Health Interview Survey. , 1988, Vital and health statistics. Series 10, Data from the National Health Survey.

[9]  J. Raskin Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. , 1999, The American journal of medicine.

[10]  C. Lavernia,et al.  Cost effectiveness and quality of life in knee arthroplasty. , 1997, Clinical orthopaedics and related research.

[11]  N. Dreyer,et al.  Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. , 1997, Arthritis and rheumatism.

[12]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[13]  E. Balazs,et al.  The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. , 1999, Clinical therapeutics.

[14]  E. Huskisson,et al.  Hyaluronic acid in the treatment of osteoarthritis of the knee. , 1999, Rheumatology.

[15]  M. Desai,et al.  Surveillance for morbidity and mortality among older adults--United States, 1995-1996. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[16]  M. Wolfe,et al.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[17]  T Minas,et al.  Chondrocyte implantation in the repair of chondral lesions of the knee: economics and quality of life. , 1998, American journal of orthopedics.

[18]  L. S. Simon,et al.  Osteoarthritis: a review. , 1999, Clinical cornerstone.

[19]  E. Yelin,et al.  Special article the economic cost and social and psychological impact of musculoskeletal conditions , 1995 .

[20]  L. Callahan,et al.  Arthritis and women's health: prevalence, impact, and prevention. , 1996, American journal of preventive medicine.

[21]  N. Bellamy,et al.  Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. , 1999, Osteoarthritis and cartilage.

[22]  John A. Astin Why Patients Use Alternative Medicine: Results of a National Study , 1999 .

[23]  J. Couzin Beefed-Up NIH Center Probes Unconventional Therapies , 1998, Science.

[24]  B. P. Smith,et al.  Cartilage injuries: a review of 31,516 knee arthroscopies. , 1997, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[25]  B. Ainsworth,et al.  Physical activity and self-reported, physician-diagnosed osteoarthritis: is physical activity a risk factor? , 2000, Journal of clinical epidemiology.

[26]  Gordon B. Hazen,et al.  A Cost-effectiveness Analysis of Total Hip Arthroplasty for Osteoarthritis of the Hip , 1996 .

[27]  M. Hochberg,et al.  Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. , 1999, The American journal of medicine.

[28]  R. Moskowitz,et al.  Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. , 1998, The Journal of rheumatology.

[29]  M. Griffin,et al.  Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. , 1998, The American journal of medicine.

[30]  R. E. Outerbridge THE ETIOLOGY OF CHONDROMALACIA PATELLAE , 1961 .

[31]  J. Fries Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[32]  Eric Lejeune,et al.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial , 2001, The Lancet.

[33]  P. Dieppe,et al.  The Bristol 'OA500 study': progression and impact of the disease after 8 years. , 2000, Osteoarthritis and cartilage.